EGFR Positive Lung Cancer UK
@egfruk
The only UK charity for EGFR+ lung cancer advocacy, empowerment & support 💜 Our community offers hope & learning for those living with EGFR+. Get involved ⤵
ID: 1096359148332204032
https://linktr.ee/egfrpositivelungcanceruk 15-02-2019 10:42:45
717 Tweet
1,1K Followers
562 Following
Excellent session highlighting that the UK is leading the way in early-phase trials combining drug-radiotherapy A standout example is the CONCORDE trial ➡️Platform trial incorporating multiple DDR inhibitors ➡️TITE-CRM Bayesian design ➡️Randomised controlled arm Leeds CTRU Cancer Research UK
Watch Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, Luis Paz-Ares, MD, PhD, & Joshua Sabari, MD (Joshua Sabari, MD) discuss the latest EGFR-MUTATED #NSCLC updates from #WCLC24 - to participate, visit: bit.ly/24EGFRLungT x.com/i/broadcasts/1…
The combination of tepotinib and osimertinib provided clinical benefit and had a manageable toxicity profile in patients with EGFR-mutated NSCLC whose disease progressed on frontline osimertinib and had MET amplification. Journal of Clinical Oncology #lcsm #oncology onclive.com/view/tepotinib…
OA02.03 - Amivantamab/lazertinib vs. osi in 1st line EGFR+ advanced NSCLC: Longer f/u of MARIPOSA by Shirish Gadgeel - mOS: NE with ami/laz vs. 37.3 months with osi (HR 0.77) - 61% alive at 3 years with ami/laz vs. 53% with osi Important update from MARIPOSA #WCLC24
.@NarjusFlorezMD discusses taking into consideration patient preferences in choosing between the various options currently available for management of EGFR positive metastatic #NSCLC Oncology Brothers
Great discusison by Alfredo Addeo MD on #FURTHER Firmonertinib has clear activity against EGFR PACC. Note AEs (e.g. rash) that could impact QOL. Need more understanding of firmonertinib's activity on various compound PACC mutations (e.g. PACC-PACC, classical-PACC). #WCLC24
The benefits of #research means that the #lungcancer treatment landscape is becoming more complex for clinicians and patients. Dr JessicaJLinMD walks us through how to consider some options for ALK, KRAS & EGFR in a review of several trials at #WCLC24 #ResearchSavesLives #LCSM
In this #WCLC24 episode, Narjust Florez, MD, FASCO discusses daily highlights. Xiuning Le MD PhD reports updated results of BAY 292708, & Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study. RadOncResearch adds her perspective of the POLESTAR trial evaluating EGFR therapy: bit.ly/WCLC24Mon